PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Overview PART 05: Market landscape • Overview • Market size and forecast • Five forces analysis PART 06: Segmentation by infection type • Overview • CAUTIs • SSIs • CLABSIs • Respiratory infections PART 07: Segmentation by end-user • Overview • Hospitals and ICUs • Outpatient care centers • LTCFs • Others PART 08: Segmentation by geography • Overview • Americas • EMEA • APAC PART 09: Decision framework PART 10: Drivers and challenges • Market drivers • Market challenges PART 11: Market trends • Emergence of innovative techniques to remove biofilms • Decrease in regulatory approvals of antibiotics • Focus on early diagnosis and preventive medicine • Cost burden of HAIs on patients and hospitals PART 12: Vendor landscape • Competitive scenario PART 13: Key vendor analysis • AstraZeneca • GlaxoSmithKline • Merck • Pfizer • Other prominent vendors PART 14: Appendix • List of abbreviations List of Exhibits Exhibit 01: Prevention, diagnosis, and treatment methods of HAIs Exhibit 02: Global HAI control market: Overview 2016-2021 Exhibit 03: Global HAI control market 2016-2021 ($ million) Exhibit 04: Factors impacting global HAI control market Exhibit 05: Five forces analysis Exhibit 06: Global HAI control market: Segmentation by infection type 2016 and 2021 (% share) Exhibit 07: Global HAI control market for CAUTIs 2016-2021 ($ million) Exhibit 08: Global HAI control market for SSIs 2016-2021 ($ million) Exhibit 09: Global HAI control market for CLABSIs 2016-2021 ($ million) Exhibit 10: Global HAI control market for respiratory infections 2016-2021 ($ million) Exhibit 11: Global HAI control market: Segmentation by end-user 2016 and 2021 (% share) Exhibit 12: Global HAI control market: Overview of segmentation by end-user Exhibit 13: Global HAI control market by hospitals and ICUs 2016-2021 ($ million) Exhibit 14: Global HAI control market by outpatient care centers 2016-2021 ($ million) Exhibit 15: Global HAI control market by LTCFs 2016-2021 ($ million) Exhibit 16: Global HAI control market by others 2016-2021 ($ million) Exhibit 17: Global HAI control market: Segmentation by geography 2016-2021 (% share) Exhibit 18: Global HAI control market: Overview of segmentation by geography Exhibit 19: HAI control market in Americas: Overview Exhibit 21: HAI control market in Americas 2016-2021 ($ million) Exhibit 22: HAI control market in EMEA: Overview Exhibit 24: HAI control market in EMEA 2016-2021 ($ million) Exhibit 25: HAI control market in APAC: Overview Exhibit 27: HAI control market in APAC 2016-2021 ($ million) Exhibit 28: Factors contributing to infections among aging people Exhibit 29: Annual cost of various types of HAIs (% share) Exhibit 30: Infection preventionists: Roles in preventing HAIs Exhibit 31: Types and number of positions for infection preventionists in US Exhibit 32: Discovery of antibiotics 1900-2010 Exhibit 33: Drugs for HAIs in clinical development Exhibit 34: Strategic success factors for vendors Exhibit 35: AstraZeneca: Profile Exhibit 36: AstraZeneca: Strength analysis Exhibit 37: AstraZeneca: Strategy assessment Exhibit 38: AstraZeneca: Opportunity assessment Exhibit 39: GlaxoSmithKline: Profile Exhibit 40: GlaxoSmithKline: Strength analysis Exhibit 41: GlaxoSmithKline: Strategy assessment Exhibit 42: GlaxoSmithKline: Opportunity assessment Exhibit 43: Merck: Profile Exhibit 44: Merck: Strength analysis Exhibit 45: Merck: Strategy assessment Exhibit 46: Merck Group opportunity assessment Exhibit 47: Pfizer: Profile Exhibit 48: Pfizer: Strength analysis Exhibit 49: Pfizer: Strategy assessment Exhibit 50: Pfizer: Opportunity assessment

AstraZeneca, GlaxoSmithKline, Merck, Pfizer, 3M, Abbott Laboratories, AbbVie, Advanced Sterilization Products, Alere, Bayer, BD, bioMérieux, Cepheid, Getinge Group, Hoffmann La-Roche, Synergy Health, and Xenex.